Cargando…

The 3′UTR signature defines a highly metastatic subgroup of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3′UTR patterns to improve postoperative risk stratification. We collected 327 publicly ava...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei, Hu, Xin, Wang, Peng, Shao, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312352/ https://www.ncbi.nlm.nih.gov/pubmed/27494850 http://dx.doi.org/10.18632/oncotarget.10975

Ejemplares similares

Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
por: Bender, R. Joseph, et al.
Publicado: (2013)

Identification of a novel signature with prognostic value in triple-negative breast cancer through clinico-transcriptomic analysis
por: Chen, Chao, et al.
Publicado: (2022)

Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
por: Wang, Lei, et al.
Publicado: (2020)

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Huang, Hao, et al.
Publicado: (2021)

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
por: Mansouri, Hanane, et al.
Publicado: (2020)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

BRCA1‐like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
por: Severson, Tesa M., et al.
Publicado: (2015)

Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery
por: Kholod, Olha, et al.
Publicado: (2022)

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
por: Wang, Biyun, et al.
Publicado: (2022)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
por: Garcia-Casado, Zaida, et al.
Publicado: (2010)

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)
por: Hacking, Sean M, et al.
Publicado: (2023)

In vivo CRISPR screens identify RhoV as a pro‐metastasis factor of triple‐negative breast cancer
por: Jin, Ming‐Liang, et al.
Publicado: (2023)

Distinct microbiological signatures associated with triple negative breast cancer
por: Banerjee, Sagarika, et al.
Publicado: (2015)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling
por: Wang, Dong-Yu, et al.
Publicado: (2019)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
por: Jiang, Yi-Zhou, et al.
Publicado: (2020)

Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer
por: Al-Taie, Zainab, et al.
Publicado: (2021)

High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
por: Cao, Zhi-Gang, et al.
Publicado: (2016)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Identification of long non-coding RNA signatures in triple-negative breast cancer
por: Tian, Tian, et al.
Publicado: (2018)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

A novel eight-gene Immune Cell-Associated Predictive Gene model to predict recurrence in triple-negative breast cancer
por: Sui, Xin-Yi, et al.
Publicado: (2023)

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023)

CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
por: Craven, Kelly E., et al.
Publicado: (2021)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Autophagy-related prognostic signature for survival prediction of triple negative breast cancer
por: Yang, Qiong, et al.
Publicado: (2022)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer
por: Wang, Wenmiao, et al.
Publicado: (2016)

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
por: Zhang, Bo, et al.
Publicado: (2023)

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
por: Tan, Antoinette R., et al.
Publicado: (2022)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r4da1mdmchg3577vfc612as8fd